Evidence map›Paper›PMID 39996141›Full record

ArticleAtherosclerosis plus2025

Safety and efficacy of edoxaban monotherapy after bioabsorbable polymer everolimus-eluting stent implantation in a human-like coronary atherosclerotic porcine model.

Daisuke Kitano, Suguru Migita, Yuxin Li, Yutaka Koyama, Katsunori Fukumoto, Sayaka Shimodai-Yamada, Akira Onishi, Daiichiro Fuchimoto, Shunichi Suzuki, Yoshiyuki Nakamura and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daisuke KitanoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Suguru MigitaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yuxin LiDivision of Advanced Cardiovascular Imaging, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yutaka KoyamaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Katsunori FukumotoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Sayaka Shimodai-YamadaDivision of Human Pathology, Department of Pathology and Microbiology, Nihon University, Tokyo, Japan.
Akira OnishiDivision of Cell Regeneration and Transplantation, Department of Functional Morphology, Nihon University School of Medicine, Tokyo, Japan.
Daiichiro FuchimotoInstitute of Agrobiological Sciences, National Agriculture and Food Research Organization (NARO), Tsukuba, Japan.
Shunichi SuzukiInstitute of Agrobiological Sciences, National Agriculture and Food Research Organization (NARO), Tsukuba, Japan.
Yoshiyuki NakamuraAgricultural Technology Research Center, Swine and Poultry Research, Saitama, Japan.
Atsushi HirayamaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Hiroyuki HaoDivision of Human Pathology, Department of Pathology and Microbiology, Nihon University, Tokyo, Japan.
Yasuo OkumuraDivision of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The combination of antiplatelet and antithrombotic drugs increases the risk of bleeding in patients with atrial fibrillation after coronary drug-eluting stent (DES) implantation. However, the appropriateness of direct-acting oral anticoagulant (DOAC) monotherapy at the time of stent implantation remains uncertain. The objective of this study was to evaluate the safety and efficacy of DOAC monotherapy, specifically using factor Xa inhibitors such as edoxaban, in a low-density lipoprotein receptor knockout (LDL-R Methods: We evaluated the safety and efficacy of edoxaban monotherapy in the LDL-R Results: Edoxaban monotherapy demonstrated a significantly thinner neointimal layer (120.0 [92.5-160.0] μm vs. 210.0 [180.0-240.0] μm, Conclusions: Edoxaban monotherapy demonstrated superior efficacy in suppressing neointimal hyperplasia and stabilizing coronary plaques compared to DAPT with equivalent safety in preventing in-stent thrombus formation. These results provide important preclinical evidence supporting the potential of DOAC monotherapy as an antithrombotic strategy after DES implantation and warrant further investigation in clinical trials.

Indexed as

Atrial fibrillationDrug-eluting stentEdoxabanHistologyOptical coherence tomographyPorcine model

Identifiers

PMID39996141
PMCPMC11848492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.